HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia

Basit Öğe Kaydı
dc.authoridKaya, Coşkun / 0000-0002-7445-2304
dc.authoridAydın, Cemil / 0000-0002-7271-5748
dc.authorwosidKaya, Coşkun / AAD-5730-2020
dc.contributor.authorKaya, Coşkun
dc.contributor.authorÇalışkan, Selahattin
dc.contributor.authorSungur, Mustafa
dc.contributor.authorAydın, Cemil
dc.date.accessioned2021-11-01T15:05:54Z
dc.date.available2021-11-01T15:05:54Z
dc.date.issued2021
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractAims To evaluate the diagnostic significance of the novel index combining preoperative haemoglobin, albumin levels, lymphocyte and platelet counts (HALP) in prostate cancer (PCa) patients. Methods Between 1 January 2015 to 31 December 2018 at the Hitit University Erol Olcok Education and Research Hospital 225 patients who had undergone transrectal ultrasound guided prostate biopsy or prostate surgery were analysed retrospectively. A total of patients, 155 had benign prostate hyperplasia (group 1) and 70 had PCa (group 2). The preoperative serum levels of haemoglobin, albumin, lymphocyte counts and platelet counts were recorded. The HALP scores and the sub-parameters of this index for each of the two groups were compared. Results The total Prostate-Specific Antigen (PSA), albumin and lymphocyte differences between the groups were statistically significant (P = 0.0002, P = 0.0001, P = 0.005). The median value of HALP scores in Group 1 and 2 were 49.43 and 51.2, respectively, and this was not statistically significant between groups (P =0 .737). The HALP score had the least Area Under Curve (AUC) value compared with the others (0.514). The AUC of Albumin was larger than PSA for diagnostic efficacy in PCa patients (0.696-0.656). However, albumin levels were statistically significant compared with platelet count and the HALP score (P = 0.0033, P = 0.0068), except PSA and lymphocyte (P = 0.4580, P =0 .1717). Conclusion Further prospective clinical studies that include more patients from multiple centres are needed to show the diagnostic role of the HALP score and its compounds on the patients with PCa.
dc.identifier.citationKaya, C., Caliskan, S., Sungur, M., & Aydın, C. (2021). HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia. International Journal of Clinical Practice, 75(3).
dc.identifier.doi10.1111/ijcp.13766
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue3en_US
dc.identifier.pmid33074558
dc.identifier.scopus2-s2.0-85096688828
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1111/ijcp.13766
dc.identifier.urihttps://hdl.handle.net/11491/7439
dc.identifier.volume75en_US
dc.identifier.wosWOS:000587564900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydın, Cemil
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal Of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHALPen_US
dc.titleHALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu